Eiger BioPharmaceuticals Inc (EIGR.OQ)
23 Mar 2018
* EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM
* EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
Eiger BioPharmaceuticals Inc said on Tuesday it would stop development of its blood pressure drug after it failed in a mid-stage study, sending its shares plunging about 46 percent.
Jan 16 Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a mid-stage study.
BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal
* EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT
* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage:
* Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals as of Oct 31 - SEC filing Source text: (http://bit.ly/2mbmToK) Further company coverage:
* Eiger Biopharmaceuticals reports third quarter 2017 financial results
* Eiger Biopharmaceuticals announces closing of public offering of common stock and exercise in full of underwriter's option to purchase additional shares Source text for Eikon: Further company coverage:
* EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK